Ann Surg Oncol (2017) 24:2777–2784 DOI 10.1245/s10434-017-5921-4 OR IG INA L A R TIC L E – PA NC REATIC TU MO RS A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma 1 1 1 1 Keiichi Okano, MD, PhD, FACS , Hironobu Suto, MD , Minoru Oshima, MD, PhD , Eri Maeda, MD , 1 1 2 Naoki Yamamoto, MD, PhD , Keitaro Kakinoki, MD, PhD , Hideki Kamada, MD, PhD , Tsutomu Masaki, MD, 2 3 3 1 PhD , Shigeo Takahashi, MD , Toru Shibata, MD, PhD , and Yasuyuki Suzuki, MD, PhD Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan; Department of Radiation Oncology, Faculty of Medicine, Kagawa University, Miki-cho, Kagawa, Japan ABSTRACT for Adverse Events (CTCAE) version 4.0] were anorexia Background. The ideal neoadjuvant treatment protocol (7%), nausea (5%), neutropenia (4%), and leukopenia for patients with pancreatic cancer (PDAC) remains (4%). No patient experienced grade 4 toxicity. Pathologi- unclear. We evaluated the efﬁcacy and safety of neoadju- cally negative margins (R0) were achieved in
Annals of Surgical Oncology – Springer Journals
Published: Jun 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud